Triveni Bio raises $65M Series C ahead of upcoming eczema readouts
What's the deal? Triveni Bio has raised $65 million in a Series C round, announced in June 2026. The biotech is developing treatments for eczema, with its second asset entering clinical studies in May 2026.
Why now? The timing aligns with Triveni's expanding clinical pipeline. Having recently moved a second eczema candidate into clinical trials, the company needs capital to fund upcoming readouts and advance its programmes.
What could go wrong? Eczema is an increasingly crowded therapeutic area, with several established and emerging treatments competing for market share. Clinical readouts carry inherent risk — disappointing data could undermine the company's position and make future fundraising harder.
The signal: Triveni Bio's $65 million Series C underscores sustained investor appetite for late-stage immunology and inflammation biotechs taking a genetics-informed approach to drug development. With two clinical-stage eczema assets now in its pipeline, the company is building a differentiated portfolio in a therapeutic area where payers and patients alike are still seeking better options despite growing competition.
Read more: Endpoints News
